541304 — Indo US Bio-Tech Share Price
0.000.00%
Last trade - 00:00- IN₹5.90bn
- IN₹6.03bn
- IN₹728.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.41 | ||
| Price to Tang. Book | 9.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.53 | ||
| EV to EBITDA | 52.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 15.96% | ||
| Return on Equity | 15.43% | ||
| Operating Margin | 13.64% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 397.61 | 400.87 | 500.59 | 617.45 | 728.36 | n/a | n/a | 15.56% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -6.29 | +101.05 | +18 | -9.27 | +9.5 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Indo US Bio-Tech Limited is engaged in research and development throw breeding, production of seeds, processing, packing and marketing of hybrid and open pollinated varieties of agricultural crops. It is also engaged in educating the local farmers by demonstration of various cultivated research crops. Its product portfolio includes a diversified variety of agriculture seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, cumin, coriander and others. It has a distribution network in the state of Gujarat, Maharashtra, Madhya Pradesh, Chhattisgarh, Rajasthan, Himanchal Pradesh, Punjab, Bihar, Uttar Pradesh, Karnataka, Jharkhand and others. It also exports to many countries, namely the United States, New Jersey, Palestine, Maimi USA, Cameroon, Kuwait, Sri Lanka and Mauritius.
Directors
- Rinku Jethva CFO
- Dimpy Joshi CCO
- Jagdish Ajudia MDR (51)
- Maltiben Ajudia EDR
- Priyanka Ajudia EDR
- Shilpa Thumar IND (33)
- Ritaben Kikani NID
- Neha Patel NID (43)
- Last Annual
- March 31st, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- February 4th, 2004
- Public Since
- May 11th, 2018
- No. of Employees
- 51
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Bombay Stock Exchange
- Shares in Issue
- 20,052,000
- Address
- Sola Road, Ahmedabad, 380061
- Web
- https://indousagriseeds.com/
- Phone
- +91 7927491807
- Contact
- Dimpy Joshi
- Auditors
- Gautam N Associates
Upcoming Events for 541304
Q3 2025 Indo Us Bio-Tech Ltd Earnings Release
Similar to 541304
Jeevan Scientific Technology
Bombay Stock Exchange
Shree Ganesh Remedies
Bombay Stock Exchange
Transgene Biotek
Bombay Stock Exchange
Vanta Bioscience
Bombay Stock Exchange
Vivo Bio Tech
Bombay Stock Exchange
FAQ
What is the Indo US Bio-Tech share price?
As of Today at 21:18 UTC, shares in Indo US Bio-Tech are trading at IN₹294.00. This share price information is delayed by 15 minutes.
How has the Indo US Bio-Tech share price performed this year?
Shares in Indo US Bio-Tech last closed at IN₹294.00 and the price had moved by +20.29% over the past 365 days. In terms of relative price strength the Indo US Bio-Tech share price has underperformed the S&P BSE 100 Index by -11.83% over the past year.
What are the analyst and broker recommendations for Indo US Bio-Tech?
There is no consensus recommendation for this security.
Find out moreWhat is the Indo US Bio-Tech dividend yield?
Indo US Bio-Tech does not currently pay a dividend.
Does Indo US Bio-Tech pay a dividend?
Indo US Bio-Tech does not currently pay a dividend.
When does Indo US Bio-Tech next pay dividends?
Indo US Bio-Tech does not currently pay a dividend.
How do I buy Indo US Bio-Tech shares?
To buy shares in Indo US Bio-Tech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Indo US Bio-Tech?
As of the previous close price of IN₹294.00, shares in Indo US Bio-Tech had a market capitalisation of IN₹5.90bn.
Where are Indo US Bio-Tech shares listed?
Here are the trading details for Indo US Bio-Tech:
- Country of listing: India
- Exchange: BSE
- Ticker Symbol: 541304
What kind of share is Indo US Bio-Tech?
Based on an overall assessment of its quality, value and momentum Indo US Bio-Tech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Indo US Bio-Tech share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Indo US Bio-Tech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Indo US Bio-Tech. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +0.99%.
As of the last closing price of IN₹294.00, shares in Indo US Bio-Tech were trading +25.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Indo US Bio-Tech PE Ratio?
The Indo US Bio-Tech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹294.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Indo US Bio-Tech?
Indo US Bio-Tech's management team is headed by:
- Rinku Jethva - CFO
- Dimpy Joshi - CCO
- Jagdish Ajudia - MDR
- Maltiben Ajudia - EDR
- Priyanka Ajudia - EDR
- Shilpa Thumar - IND
- Ritaben Kikani - NID
- Neha Patel - NID